cyrilzakka/clinical-trials huggingface dataset:
Middle East African Registry Women CardioVascular Disease

The MEA cardiology societies have joined forces to tackle the issue by establishing a tangible real-world data registry in every MEA country. This endeavor has resulted in the development of a multicenter registry called MEA-WCVD, which is being sponsored by each national cardiology society from participating countries. All data gathered will be consolidated into a singular registry for thorough analysis. Country specific analysis will be performed.


Eligibility Criteria:
Inclusion Criteria:

* All incomers in Cardiovascular (CV) diseases in hospital or out hospital facilities with one of the 4 diagnosis (Heart Failure (HF), Atrial fibrillation (AF), Valvular Heart disease (VHD), ischemic heart disease (IHD)
* Age over 18 years old
* Men and Women
* Signature of consent form

Exclusion Criteria:

Patients with diseases other than the 4 previously mentioned in inclusion criteria
Preterm Infants Born to Homeless Mothers.

In recent years, the number of homeless patients who are accommodated by the SAMU social has increased. These patients are in a situation of financial, but also often social and psychological precariousness. The literature already shows us that precariousness and homelessness are a risk factor for prematurity, but also for the patients themselves, a risk of more frequent recourse to emergency services and of late consultation for advanced pathologies.

The objective of this study is to evaluate the fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers.

The hospital of Pontoise is the largest maternity hospital in the department (Val d'Oise, 95) with 4449 births in 2021. It has a type 3 neonatal intensive care unit where approximately 150 premature babies under 32 weeks of age are hospitalized each year, including 80 premature babies under 28 weeks of age. These children require a specific and prolonged follow-up after hospitalization, including medical consultations to evaluate their neurodevelopmental development, but also the prevention of RSV infection (Respiratory Syncitial Virus).

In recent years, the number of homeless patients who are accomodated by the SAMU social has increased. These patients are in a precarious financial, but also often social and psychological situation. The literature already shows us that precariousness and homelessness are a risk factor for prematurity, but also for the patients themselves, a risk of more frequent recourse to emergency services and late consultation with advanced pathologies.

The aim of this study is to evaluate the fate and quality of medical follow-up of children born very premature (≤33SA) to homeless mothers, by answering the following questions:

* What about the follow-up of their very premature child?
* How does the department organize itself to ensure optimal follow-up for these patients?

Eligibility Criteria:
Inclusion Criteria :

All infants born at or below 33SA:

* Born between January 2019 and December 2021
* At the René Dubos Hospital in Pontoise
* Whose mother did not have a fixed address at the time of discharge.

NB: Mothers who do not read French well will have the study explained to them by the doctor who follows their child during a consultation, or by telephone.

Exclusion Criteria :

- Opposition of the mothers
Role of Ginkgo Biloba Extract in IUGR

The use of herbal medicinal products is increasing enormously in recent years, mainly among women, who use them for the most varied purposes, such as in menstrual problems, menopausal symptoms, mood disturbances and to strengthen their bones. Most of these benefits are due to the flavonoids present in these products. These flavonoids have anticarcinogenic, antiviral, antioxidant and antiinflammatory activities, as well as being used in the treatment of osteoporosis, menopausal symptoms and cardiovascular diseases . Besides the benefits from the consumption of flavonoids, little is known about their safety and potentially harmful toxic effects, such as mutagenicity and genotoxicity which might occur if taken in large doses . Safety of Ginkgo biloba during pregnancy or lactation was not criticized in literature. Roasted and raw ginkgo seed were not reported in the evidence-based medicine literature as being either safe or contraindicated in pregnancy or lactation. A higher incidence of postpartum hemorrhage was reported in the literature when associated with a 3-month ingestion of Ginkgo Biloba extract. Flavonoids are components of Ginkgo biloba L. (Ginkgoaceae), a medicinal plant widely used by the population . G. biloba has its origin in China, Korea and Japan where its fruits and leaves have been used as food and medicine for a long time.

The extract of G. biloba (EGb) is composed of different terpene trilactones, i.e., ginkgolides A, B, C, J and bilobalide, many flavonol glycosides, biflavones and alkylphenols . The major flavonoids in the extract are kaempferol, quercetin and isorhamnetin\] whose metabolites were found in the blood of rats and in human urine after oral administration of EGb. Due to its actions as an anti-inflammatory and antioxidant, EGb has been largely used in the treatment of Alzheimer's disease, pre-menstrual syndrome, cerebrovascular insufficiency and peripheral arterial occlusive disease . In folk medicine, EGb is used as a vermifuge, to induce labor, for the treatment of bronchitis, chronic rhinitis, chilblains, arthritis and edema . The aim of this study was to evaluate the effect of oral supplementation of Ginkgo Biloba extract on the fetal weight as well as feto-maternal blood flow in cases of intrauterine growth restriction.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant women in their third trimester (28-30 weeks of gestation).
* Pregnant women whose pregnancy was complicated with intra uterine growth restriction (IUGR).
* Normal Doppler indices in uterine, umbilical and middle cerebral arteries at time of recruitment.

Exclusion Criteria:

* Multiple pregnancies,
* Hypertension,
* Fetal congenital anomalies,
* Previous history of congenital anomalies or chromosomal abnormalities.
* Diabetes Mellitus
* Premature pre-labor rupture of membranes
* Antepartum hemorrhage
Growth Chart Parameters, Risk Factors

comparison between growth chart parameters and different risk factors which can cause abnormal growth chart parameter

Infant growth is defined as a positive change in body size over a period of time, and it is a sensitive predictor of an individuals' health. An inappropriate growth pattern indicates nutritional disorders, chronic and infectious diseases in infants. Early growth rate is related to adulthood health, such that it is important to develop the concept of appropriate growth for parents, in other to detect children with abnormal growth rates, as soon as possible .Weight and height of preschool children are the most common anthropometric measurements, to investigate a child's growth rate. Weight is the simplest and most reliable anthropometric measurement, and may be used as an indicator of childhood infection. On the other hand, height summarizes various measures of nutritional conditions in the first two decades of a human's life. Many children younger than 5 years in developing countries are exposed to multiple risks, including poverty, malnutrition, poor health, and unstimulating home environments, which detrimentally affect their cognitive, motor, and social-emotional development.

Eligibility Criteria:
Inclusion Criteria:

* All children attending primary health care units in Assiut governorate aged from one year to five year

Exclusion Criteria:

* 1. congenital anomalies 2. chronic diseases (D.M , thyroid dysfunction)
Effects of Different Postures and Ventilator Flow Waveforms on the Cuff Leak Test

the purpose of this study is to analyzes the factors influencing the results of cuff leak test, in order to improve the cuff leak test on the accuracy of the prediction on airway edema after extubation.


Eligibility Criteria:
Inclusion Criteria:

* Intubation less than 24 hours before amitting respiratory intensive care unit;

Exclusion Criteria:

* unstable hemodynamics;PEEP≥10cmH2O or FiO2≥0.8
Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)

Development of a new MS-based biomarker for the early and sensitive diagnosis of Maroteaux-Lamy disease from blood

Maroteaux-Lamy disease (MPS VI) is a lysosomal storage disease inherited in an autosomal recessive pattern. The responsible mutations lie in ARSB (5q11-q13), the gene that encodes the enzyme arylsulfatase B. The phenotype results from defective dermatan sulfate break-down with lysosomal accumulation. This accumulation of glycosaminoglycans is responsible for the widespread signs and symptoms found in this disease. Bone destruction in shoulders, hips and skull is often seen by the second decade of life and may become evident later in the knees and spine. Early growth may be normal but eventually slows resulting in short stature. Dysplasia of bones comprising these joints leads to stiffness and restricted movement. The face is dysmorphic with coarse features. Bone dysplasia and facial dysmorphism may be seen at birth.

Myelopathy and even tetraplegia can result from vertebral compression. Intelligence is often normal although more severely affected individuals may have some cognitive defects due to impaired vision and hearing. Hepatosplenomegaly is common and compromised respiratory function can result in reduced physical stamina. The tongue is usually enlarged. Accumulation of dermatan sulfate in heart valves may produce insufficiency or restriction of outflow. A diagnosis of Maroteaux-Lamy disease can be confirmed by screening for the common genetic mutations or measuring the level of the arylsulfatase B enzyme activity in a blood sample -- a test that has 100 percent accuracy. Once Maroteaux-Lamy disease is diagnosed, testing of all family members and consultation with a professional geneticist is recommended. Carriers are most reliably identified via genetic mutation analysis.

New methods, like mass-spectrometry give a good chance to characterize in the blood (plasma) of affected patents specific metabolic alterations that allow to diagnose in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to develop new biochemical markers from the plasma of the affected patients helping to benefit the patient by an early diagnose and thereby with an earlier treatment.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent will be obtained from the patient or the parents before any study related procedures.
* Patients older than 12 months
* The patient has a diagnosis of Maroteaux-Lamy disease

Exclusion Criteria:

* No Informed consent from the patient or the parents before any study related procedures
* Patients younger than 12 months
* The patient has no diagnosis of Maroteaux-Lamy disease
Evaluation of Safety and Tolerability of Ocular Lubricants

The purpose of this study is to evaluate the safety profile of test formulations for an artificial tear product versus a comparator product.

Subjects will be randomized to one of five different treatment sequences. Subjects will attend 6 scheduled visits with an expected individual duration of participation of 11 to 42 days. This study will be conducted in Australia.

Eligibility Criteria:
Key Inclusion Criteria:

* Able to understand and sign an informed consent form.
* Willing and able to attend all study visits as required by the protocol.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Any known active ocular disease.
* Any systemic condition that, in the opinion of the investigator, may affect a study outcome variable.
* Any ocular injury to either eye in the past 12 weeks prior to screening.
* Other protocol-defined exclusion criteria may apply.
Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy System

The purpose of the study is to collect survey data on the use of the OEC Elite Mobile Fluoroscopy System based on the routine clinical use of the device.

This prospective clinical study is being conducted to acquire image guidance adequacy data from physicians conducting clinically-indicated vascular, gastrointestinal (GI), urology and pain management procedures for engineering use, as deemed appropriate by the Sponsor, for the investigational OEC Elite Mobile Fluoroscopy System (OEC Elite) in the vascular configuration. Clinical procedures included in this study will involve three (3) anatomical regions of interest - extremities and neck, thorax, and abdomen and pelvis. These regions are being targeted because they represent the range of clinical applications and anatomical regions intended for OEC Elite in the vascular configuration.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female between the ages of 18 and 75 years (≥18 and ≤75 years old);
2. Clinical indication for a vascular, gastrointestinal (GI), urology or pain management procedure for which mobile fluoroscopy has been prescribed;
3. Able and willing to comply with study procedures; and
4. Able and willing to provide written informed consent to participate.

Exclusion Criteria:

1. Pregnant or suspected to be pregnant based on the opinion of and as documented by a medically qualified physician investigator;
2. Expected to be at increased risk due to study participation (e.g. due to allergies, sensitivities), in the medical opinion of an investigator; or
3. Previously participated in this study, or enrolled in another active GEHC study or other research study that could be expected to interfere with participation in study procedures, in the opinion of the investigator.
Prevalence of Impaired Glucose Tolerance (IGT) in Patients With Frozen Shoulder

Idiopathic Adhesive Capsulitis, Frozen Shoulder is a condition in which there is a limitation and significant pain at the shoulder and it is increases with shoulder movements. The causes are not clear. The prevalence of this condition is four times higher in diabetic patient compare to the general population.

The relation between frozen shoulder and impaired glucose tolerance remain unclear.

Our hypothesis is that patients with no diabetes and that suffer from frozen shoulder have a higher prevalence of impaired glucose tolerance than the general population age matched.


Eligibility Criteria:
Inclusion Criteria:

1. age 30-60.
2. previous Xray that eliminates other disease of the shoulder.
3. previous US that eliminates tendon shoulder rupture
4. shoulder movement in all directions, with limitation in the external rotation (at least 50%)

Exclusion Criteria:

1. Diagnosed Diabetes (pregnancy diabetes includes)
2. Taking Hyperglycemic medications (like Steroids)
3. Fracture or operation in the shoulder before the diagnosis of frozen shoulder.
Target Temperature Management In Myocardial Infarction - A Pilot Study

The primary goal in the treatment of acute myocardial infarction is to reperfuse the ischemic myocardium to reduce infarct size. Animal data and human data suggest that whole-body cooling to temperatures below 35°C before revascularisation can additionally reduce infarct size and therefore improves outcome in these patients.

The purpose of the study is to determine the feasibility and safety of a combined cooling strategy started in the out-of-hospital arena for achieving pre-reperfusion hypothermia in patients with acute st-elevation myocardial infarction.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 75 years
* Immediately transfer to cath-lab is possible
* Anterior or inferior ST-Elevation myocardial infarction
* ST-Segment elevation of \>0.2mV in 2 or more anatomically contiguous leads
* Duration of symptoms \<6 hours

Exclusion Criteria:

* Participation in another study
* Patients presenting with cardiac arrest
* Tympanic temperature of \<35.0°C prior enrolment
* Thrombolysis therapy
* Previous myocardial infarction in medical history
* Previous percutaneous coronary intervention or coronary artery bypass graft
* Severe heart failure (defined as a New York Heart Association (NYHA) score of III or IV), Killip class II through IV at presentation
* Clinical signs of infection
* End-stage kidney disease or hepatic failure
* Recent stroke (within the last six month)
* Conditions that may be exacerbated by hypothermia, such as haematological dyscrasias, oral anticoagulant treatment with international normalized radio \>1.5, severe pulmonary disease
* Pregnancy. Women of childbearing potential are excluded
* Allergy to meperidine, buspirone, magnesium, or polyvinyl chloride
* Use of a monoamine oxidase inhibitor such as selegiline in the previous 14 days
To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels

The purpose of this study is to determine the safety and clinical outcomes of the Absorb BVS for daily use in patients with de novo lesions in previously untreated vessels.

ABSORB UK registry is a prospective, single arm, post-market registry designed to:

* Provide ongoing post-market surveillance for documentation of safety and clinical outcomes of the Absorb Everolimus Eluting BVS System in daily percutaneous coronary intervention (PCI) practice per Instructions for Use (IFU, on-label use).
* Collect additional information (e.g. acute success) to evaluate handling and implantation of Absorb BVS by physicians under a wide range of commercial use conditions and following routine clinical practice.

Eligibility Criteria:
Inclusion Criteria:

The inclusion criteria must follow the most recent IFU which may include but are not limited to the following:

* Patient must be at least 18 years of age at the time of signing the Informed Consent Form
* Patient is to be treated for de novo lesions located in previously untreated vessels.
* Patient must agree to undergo all required follow-up visits and data collection.

Exclusion Criteria:

The exclusion criteria must follow the most recent IFU which may include but are not limited to the following:

* Inability to obtain a signed informed consent from potential patient.
* Patient belongs to a vulnerable population (per investigator's judgment, this also includes people with a direct link (hierarchical or financial benefit) to the registry Doctor or the registry Sponsor).
Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

The purpose of this study is to explore the efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were previously unsuccessfully treated with other oral antipsychotics.

This is a single arm (one group of participants), multi-center, 6-month study to explore the tolerability, safety and efficacy of flexibly dosed paliperidone ER in participants with schizophrenia previously unsuccessfully treated with an oral antipsychotic medication. Antipsychotic medications are drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders. Unsuccessfully treated means that, despite the participant was treated with an adequate dose of an appropriate oral antipsychotic for an adequate period of time, previous treatment is considered unsuccessful due to lack of efficacy, lack of tolerability or safety, lack of compliance and/or other reasons. Throughout the study the investigators will adjust the dosage of each participant based on the individual needs. In general, the recommended paliperidone ER dose will be 6 milligram once daily. Participants can be either in- or outpatients and they may take their study drug with or without food. Participants who will complete this 6-month study and would like to continue will be eligible to be enrolled in an extension phase until paliperidone ER is available.

Eligibility Criteria:
Inclusion Criteria:

* Participant diagnosed with schizophrenia
* Participant's previous treatment of schizophrenia is considered unsuccessful
* Participant is healthy on the basis of a physical examination and vital signs
* Women must be postmenopausal, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study
* Be willing and able to fill out self-administered questionnaires

Exclusion Criteria:

* Have used clozapine or Risperdal CONSTA during the last month, or have received any other conventional drug used to treat psychosis during the last 3 months
* Judged to be at high risk for adverse events, violence or self-harm
* Inability to swallow the study medication whole with the aid of water
* Pregnant or breast-feeding female
* History or current symptoms of tardive dyskinesia (involuntary movements of the facial muscles and tongue)
Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (1 g) for 6 months in subjects with peripheral arterial disease (PAD); non-claudication or claudication) improves your walking ability. Previous studies with heart failure patients had shown that carnosine supplementation increases walking capacity in these patients.

The objectives of this double-blinded longitudinal study are to determine whether carnosine supplementation (2 g) for 6 months in subjects with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. In this pilot study there will be enrolled 120 subjects that will be divided into placebo (n=60) and carnosine groups (n=60). The distance covered on the 6-minute walk test (6-MWT) and the pain free walking capacity on the treadmill before and after the placebo or carnosine supplementation will be measured. Ankle branchial index (ABI), blood flow by magnetic resonance imaging (MRI) and laser doppler flowmetry (LDF) before and after the carnosine and placebo supplementation will be also measured. In addition, the carnosine will be measured by 1HMRS, global metabolomics and proteomics in the skeletal muscle will be performed, a comprehensive lipid and metabolic panels of blood will be performed, uptake of carnosine in red blood cells (RBCs) will be measured, and carnosine aldehyde conjugates in the urine before and after 6 months of carnosine and placebo supplementation will be evaluated. Following completion of the study, the subjects will be followed up for another 3 months and examine the durability of carnosine supplementation.

Eligibility Criteria:
Inclusion Criteria:

1. Subjects between 40-80 years of age.
2. English Speaking.
3. ABI 0.4-\<0.90.
4. Willing to comply with protocol requirements.
5. Able to provide informed consent.

Exclusion Criteria:

1. Subjects with HIV, hepatitis, significant liver disease, active infection, anemia, organ transplant, renal disease requiring dialysis, lung disease requiring oxygen, significant congenital heart disease, cancer of any type, and untreated thyroid disease.
2. Diagnosis of carnosinemia.
3. Known allergy to L-carnosine or meat.
4. Obesity from a known genetic defect.
5. Critical limb ischemia with below or above the knee amputations or foot ulcers.
6. Participating in other clinical trials.
7. Presence of significant injury within 30 days before enrollment.
8. Patients using dual antiplatelet therapies will be excluded for muscle biopsy.
9. Poorly controlled diabetes (HbA1c \>9% within 6 months)
10. Subjects with a baseline 6MWT of less than 152.0 meter (498ft) or greater than 487.7 meters (1600ft)
11. Subjects with internal metallic objects in body (cannot have MRI)